The lawsuit accuses Abbott of creating products called “transition formulas,” “follow-on formulas,” “weaning formulas” and “toddler milks” to boost earnings as infant formula sales ...

There were unforgiveable shortcomings in management, which included critical information not reaching senior officials as ...

Abbott, a health care products conglomerate ... by the U.S. Food and Drug Administration (FDA). Yet unlike baby formula, the toddler milk products are not regulated by the FDA and are potentially ...

She explains that, while the toddler years are hugely important in terms of brain and body growth, and that a focus on ...

I think Abbott will win these baby formula cases. Yet, who wants that overhang, right? Certainly not Wall Street. So what does this stock do? It languishes. Who knows how quickly things can change ...

(Read the full complaint below.) Abbott loses $500 million baby formula verdict Why Abbott and Dexcom buried the hatchet in their glucose monitor patent fight Abbott tries to claw back $24.3 ...

The alarm certainly sounded long and loud in 2022 when Abbott recalled Similac, Alimentum, and EleCare powdered infant formulas after an FDA investigation ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics units overshadowed strength in medical devices, sending its shares down more ...

Downside risk was primarily related to formula lawsuits, and this was restricted to one part of the business. Since then, Abbott has returned 6% while the broader market (via S&P 500) has returned ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...